2020 | Jecko Thachil, Ning Tang, Satoshi Gando, Anna Falanga, Marco Cattaneo, Marcel Levi, Cary Clark, Toshiaki Iba
The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. Elsevier grants permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights, as long as the resource centre remains active.
The article "Interim Guidance on Recognition and Management of Coagulopathy in COVID-19" by Jecko Thachil et al. discusses the management of coagulopathy in patients with COVID-19. Key points include:
1. **Introduction**: COVID-19 has led to significant mortality, with many patients developing severe organ failure and coagulopathy, a poor prognostic feature. The International Society of Thrombosis and Haemostasis (ISTH) is crucial in guiding healthcare professionals in managing this condition.
2. **Coagulation Markers at Admission**: D-dimers, prothrombin time (PT), and platelet count are key markers. Elevated D-dimers (≥0.5 mg/L) and prolonged PT are associated with poor outcomes. Thrombocytopenia is not always a consistent predictor of mortality.
3. **Monitoring Coagulation Markers**: Regular monitoring of PT, D-dimer, platelet count, and fibrinogen is essential to identify worsening coagulopathy. Fibrinogen levels can be monitored but may not be feasible in all laboratories.
4. **Management of COVID-19 Coagulopathy**: Prophylactic low molecular weight heparin (LMWH) is recommended for all hospitalized patients, including those without severe illness, to reduce mortality and protect against venous thromboembolism. LMWH also has anti-inflammatory properties, which may benefit COVID-19 patients with high levels of pro-inflammatory cytokines.
The article emphasizes the importance of early identification and management of coagulopathy in COVID-19 patients to improve outcomes.The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. Elsevier grants permission to make all COVID-19-related research available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights, as long as the resource centre remains active.
The article "Interim Guidance on Recognition and Management of Coagulopathy in COVID-19" by Jecko Thachil et al. discusses the management of coagulopathy in patients with COVID-19. Key points include:
1. **Introduction**: COVID-19 has led to significant mortality, with many patients developing severe organ failure and coagulopathy, a poor prognostic feature. The International Society of Thrombosis and Haemostasis (ISTH) is crucial in guiding healthcare professionals in managing this condition.
2. **Coagulation Markers at Admission**: D-dimers, prothrombin time (PT), and platelet count are key markers. Elevated D-dimers (≥0.5 mg/L) and prolonged PT are associated with poor outcomes. Thrombocytopenia is not always a consistent predictor of mortality.
3. **Monitoring Coagulation Markers**: Regular monitoring of PT, D-dimer, platelet count, and fibrinogen is essential to identify worsening coagulopathy. Fibrinogen levels can be monitored but may not be feasible in all laboratories.
4. **Management of COVID-19 Coagulopathy**: Prophylactic low molecular weight heparin (LMWH) is recommended for all hospitalized patients, including those without severe illness, to reduce mortality and protect against venous thromboembolism. LMWH also has anti-inflammatory properties, which may benefit COVID-19 patients with high levels of pro-inflammatory cytokines.
The article emphasizes the importance of early identification and management of coagulopathy in COVID-19 patients to improve outcomes.